Skip to main content
. 2021 May 14;12:2814. doi: 10.1038/s41467-021-22967-7

Fig. 5. ACAT regulates de novo HBV particle genesis.

Fig. 5

a HepG2-NTCP were infected with HBV in the presence of ACAT inhibition (Avasimibe), Myrcludex-B (MyrB) or DMSO. Viral uptake in 6 h was quantified by qPCR of intracellular HBV DNA. b HepG2-NTCP cells were infected with HBV (MOI 200) in the presence of ACAT inhibition (2.5 mg/ml and 5 mg/ml Avasimibe), Entecavir (ETV) or DMSO in two independent experiments with a total of six replicates. cccDNA (relative to untreated mean), HBeAg, extracellular HBV DNA (relative to untreated mean) and HBsAg were measured after 6d by either qPCR or ELISA. c HBV-infected HepG2-NTCP cells (6d post infection) were treated with ACAT inhibition (Avasimibe), ETV or DMSO in four independent replicates. Extracellular HBV DNA (relative to untreated mean) extracellular HBsAg were measured after 6d. P values determined by Kruskal–Wallis test with Dunn’s multiple comparisons test. Bars indicate median values.